{"id":"W4413122220","doi":"10.3390/curroncol32080444","title":"Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Grand River Hospital; Ottawa Hospital; Dr. H. Bliss Murphy Cancer Centre; Jewish General Hospital; University of Toronto; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"Daiichi Sankyo Europe; Eli Lilly Canada; Ipsen; Astellas Pharma; Eisai; Incyte; Allergan; Helsinn; Genomic Health; Seagen; Gilead Sciences; Amgen; Pfizer; Myriad Genetics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Tolerability; Adverse effect; Breast cancer; Multidisciplinary approach; Quality of life (healthcare); Clinical trial; Oncology; Metastatic breast cancer; Intensive care medicine; Adjuvant; Advance care planning; Internal medicine; Cancer; Palliative care; Nursing","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008428948,0.000944467,0.0009073301,0.001878118,0.004540082,0.003155887,0.003301619,0.006514273,0.02076785],"category_scores_gemma":[0.02642713,0.0007647984,0.001587819,0.001582689,0.001907744,0.001656464,0.003222161,0.005133902,0.005695207],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.03543428,"about_ca_system_score_gemma":0.2105614,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.7663824,"about_ca_topic_score_gemma":0.9351177,"domain_scores_codex":[0.9902213,0.003029771,0.0008499631,0.0003870031,0.003625972,0.001886057],"domain_scores_gemma":[0.9758792,0.003701242,0.001299868,0.0003715988,0.0129155,0.005832503],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000442297,0.0001441285,0.002030981,0.0004385704,0.00001843178,0.0005888335,0.0006511245,0.001240189,0.0004262514,0.003308353,0.8828855,0.1082235],"study_design_scores_gemma":[0.0002013853,0.0001508099,0.007324948,0.002957481,0.00004461815,0.0005943909,0.001521418,0.0009443118,0.0004019998,0.004771602,0.9809656,0.0001216652],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"methods","genre_scores_codex":[0.005746546,0.019339,0.01697049,0.7352525,0.005753809,0.004607067,0.003750782,0.001337041,0.2072428],"genre_scores_gemma":[0.08813079,0.06798761,0.2640604,0.3970601,0.003196874,0.006081236,0.006076352,0.0007399846,0.1666666],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.2336176,"threshold_uncertainty_score":0.4699868,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03220749072323967,"score_gpt":0.4056603800270666,"score_spread":0.3734528893038269,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}